Clinical care for disorders of growth hormone and for diabetes has been dominated by single-analyte biochemical targets. In GH disorders clinicians commonly follow serum insulin-like growth factor-1 (IGF-1); in diabetes care the primary target is glycated hemoglobin. The reviewed work argues this reductive approach obscures a critical regulatory relationship: circulating GH alone does not determine hepatic IGF-1 output.
The authors propose the construct of liver sensitivity to GH (LSG) as a unifying variable. Operationally, LSG is defined as hepatic GH receptor (GHR) availability that is determined by the concentration of portal insulin reaching the liver. Framing conditions along an LSG continuum moves pathologies such as type 1 diabetes, type 2 diabetes, obesity, liver failure, and acromegaly from discrete categories toward a shared mechanistic landscape.
The review develops the molecular rationale for how insulin regulates hepatocyte GHR levels and thereby gates GH-driven IGF-1 synthesis. According to the source, insulin concentration at the hepatocyte—specifically delivered via the portal circulation—modulates GHR availability and thus the capacity of GH to be translated into IGF-1 by the liver. The abstract indicates that molecular detail is provided in the full text; specific molecular pathways, intermediate proteins, or quantitative relationships were not reported in the abstract.
A central distinction emphasized is between portal insulin (insulin delivered directly to the liver from the pancreas) and systemic insulin (circulating insulin after peripheral distribution or subcutaneous administration). The authors argue that portal insulin uniquely regulates hepatic GHR availability. This distinction helps explain clinical observations such as the phenomenon in type 1 diabetes where subcutaneously administered insulin corrects peripheral glycemia but fails to restore hepatic GH sensitivity—because subcutaneous insulin does not replicate the physiological portal insulin concentrations required to normalize hepatocyte GHR and IGF-1 output.
Viewed through the LSG framework, metabolic diseases share a common axis in which portal-insulin–dependent modulation of hepatic GHR shapes IGF-1 production. In type 1 diabetes, absent endogenous pancreatic insulin lowers portal insulin and thereby impairs LSG despite systemic glycemic control with subcutaneous insulin. In type 2 diabetes and obesity, altered insulin dynamics and insulin resistance will influence portal insulin delivery and hepatic GHR regulation, shifting LSG. In liver failure or cirrhosis, hepatic dysfunction further perturbs GH/IGF-1 relationships; the review suggests IGF-1 has prognostic and potentially therapeutic relevance in cirrhosis when interpreted via LSG. The abstract does not provide quantitative measures or specific clinical thresholds for LSG across these conditions.
Applying the LSG concept to acromegaly highlights limitations of treatment strategies that focus solely on normalizing serum IGF-1. Because hepatic IGF-1 output depends not only on GH exposure but on portal-insulin–regulated GHR availability, metabolic context may produce discordant GH and IGF-1 signatures. The authors argue that current biochemical targets in acromegaly may have metabolic limitations if LSG is not considered; the abstract does not enumerate alternative targets or specific treatment changes, only presents the conceptual critique.
The LSG framework is used to reinterpret several clinical observations:
Subcutaneous insulin in type 1 diabetes corrects peripheral hyperglycemia but may leave the hepatic GH-resistant state intact because it does not restore portal-insulin concentrations that govern GHR availability.
The weight-gain liability of insulinotropic antidiabetic agents is re-examined in the context of how these drugs alter insulin delivery and potentially modify LSG; specific comparative data or effect sizes are not provided in the abstract.
GLP-1 receptor agonists produce discordant GH/IGF-1 signatures; the review revisits these patterns through the portal-insulin/LSG lens. The abstract does not report detailed mechanistic pathways or clinical trial outcomes for GLP-1 RAs.
In cirrhosis, the review highlights a prognostic and potentially therapeutic role for IGF-1 when interpreted within the LSG framework; again, the abstract notes the concept but does not provide specific prognostic markers or therapeutic protocols.
The principal clinical takeaway is a mechanistic reframing: hepatic IGF-1 production depends on a gatekeeper role for portal insulin that determines hepatocyte GHR availability and thus the effective translation of GH into IGF-1. Defining and applying LSG may allow clinicians to conceptualize metabolic diseases along a continuum instead of as isolated entities and may clarify puzzling clinical patterns such as persistent hepatic GH resistance in insulin-treated type 1 diabetes or discrepant GH/IGF-1 responses to certain antidiabetic therapies.
Limitations and gaps: the abstract does not supply numerical data, experimental results, or specific clinical recommendations. Details of the molecular mechanisms, quantitative criteria for LSG, and clinical trial evidence are not reported in the abstract and would require consulting the full review text. The authors’ stated aim is to provide a mechanistic account to inform clinicians rather than to issue prescriptive clinical guidelines.
The review advances a unifying mechanistic concept—liver sensitivity to GH (LSG)—anchored to portal insulin as a determinant of hepatic GH receptor availability and IGF-1 output. This model seeks to integrate metabolic disorders including diabetes, obesity, liver failure, and acromegaly on a single continuum and to explain clinical observations that single-analyte biochemical targets do not fully capture. Clinicians interested in the metabolic interplay of insulin, GH, and IGF-1 should consult the full article for the detailed molecular arguments and any evidence summaries that support the LSG framework.